Ikaros expression sensitizes leukemic cells to the chemotherapeutic drug doxorubicin

He,Licai; Gao,Shenmeng; Zhu,Zhenfeng; Chen,Shang; Gu,Haihua

doi:10.3892/ol.2016.4680

Ikaros expression sensitizes leukemic cells to the chemotherapeutic drug doxorubicin

Authors:
- Licai He
- Shenmeng Gao
- Zhenfeng Zhu
- Shang Chen
- Haihua Gu
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, School of Laboratory Medical and Life Science, Wenzhou Medical University, Chashan Higher Education Park, Wenzhou, Zhejiang 325035, P.R. China, Department of Internal Medicine, Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Published online on: June 7, 2016 https://doi.org/10.3892/ol.2016.4680
Pages: 1178-1182

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ikaros is an important transcription factor involved in the development and differentiation of hematopoietic cells. However, its role in the treatment of hematopoietic malignancies such as leukemia is less well understood. In the present study, it was observed by data mining of the Oncomine database that high expression levels of full‑length Ikaros (IK1) is correlated with increased sensitivity of cancer cells to treatments with chemotherapeutic drugs, including doxorubicin (DOX). To examine the functional significance of this observation, the expression of IK1 in a leukemia cell line was altered, and the response of leukemic cells to DOX treatment was analyzed. It was observed that overexpression of IK1 could enhance DOX‑induced apoptosis, while knockdown of IK1 attenuated DOX‑induced apoptosis in leukemic cells. Further experiments demonstrated that IK1 sensitized leukemic cells to DOX‑induced apoptosis, probably through upregulation of caspase‑9. These data suggest that high expression levels of IK1 may be a potential biomarker to predict responses of leukemia patients to treatment with chemotherapy.

View Figures

View References

1	Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
2	Lowenberg B, Downing JR and Burnett A: Acute myeloid leukemia. N Engl J Med. 341:1051–1062. 1999. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
4	Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001. View Article : Google Scholar : PubMed/NCBI
5	Estey EH: Treatment of acute myelogenous leukemia. Oncology (Williston Park). 16:343–352, 355–356; discussion 357, 362, 365–366. 2002.PubMed/NCBI
6	Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR and Frei E III: Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 331:896–903. 1994. View Article : Google Scholar : PubMed/NCBI
7	Appelbaum FR, Baer MR, Carabasi MH, Coutre SE, Erba HP, Estey E, Glenn MJ, Kraut EH, Maslak P, Millenson M, et al: NCCN practice guidelines for acute myelogenous leukemia. Oncology (Williston Park). 4:53–61. 2000.
8	Saultz JN and Garzon R: Acute myeloid leukemia: A concise review. J Clin Med. 5:E332016. View Article : Google Scholar : PubMed/NCBI
9	Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C and Spalla C: Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng. 11:1101–1110. 1969. View Article : Google Scholar : PubMed/NCBI
10	Tacar O, Sriamornsak P and Dass CR: Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 65:157–170. 2013. View Article : Google Scholar : PubMed/NCBI
11	Lerma-Diaz JM, Hernández-Flores G, Domínguez-Rodríguez JR, Ortíz-Lazareno PC, Gómez-Contreras P, Cervantes-Munguía R, Scott-Algara D, Aguilar-Lemarroy A, Jave-Suárez LF and Bravo-Cuellar A: In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline. Involvement of caspase cascades and IkappaBalpha phosphorylation. Immunol Lett. 103:149–158. 2006. View Article : Google Scholar : PubMed/NCBI
12	Broxterman HJ, Gotink KJ and Verheul HM: Understanding the causes of multidrug resistance in cancer: A comparison of doxorubicin and sunitinib. Drug Resist Updat. 12:114–126. 2009. View Article : Google Scholar : PubMed/NCBI
13	Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S and Sharpe A: The Ikaros gene is required for the development of all lymphoid lineages. Cell. 79:143–156. 1994. View Article : Google Scholar : PubMed/NCBI
14	Georgopoulos K, Moore DD and Derfler B: Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. Science. 258:808–812. 1992. View Article : Google Scholar : PubMed/NCBI
15	Cortes M, Wong E, Koipally J and Georgopoulos K: Control of lymphocyte development by the Ikaros gene family. Curr Opin Immunol. 11:167–171. 1999. View Article : Google Scholar : PubMed/NCBI
16	Rebollo A and Schmitt C: Ikaros, Aiolos and Helios: Transcription regulators and lymphoid malignancies. Immunol Cell Biol. 81:171–175. 2003. View Article : Google Scholar : PubMed/NCBI
17	Krysko DV, Vanden Berghe T, Parthoens E, D'Herde K and Vandenabeele P: Methods for distinguishing apoptotic from necrotic cells and measuring their clearance. Methods Enzymol. 442:307–341. 2008. View Article : Google Scholar : PubMed/NCBI
18	He LC, Gao FH, Xu HZ, Zhao S, Ma CM, Li J, Zhang S and Wu YL: Ikaros inhibits proliferation and, through upregulation of Slug, increases metastatic ability of ovarian serous adenocarcinoma cells. Oncol Rep. 28:1399–1405. 2012.PubMed/NCBI
19	Pulte D, Lopez RA, Baker ST, Ward M, Ritchie E, Richardson CA, O'Neill DW and Bank A: Ikaros increases normal apoptosis in adult erythroid cells. Am J Hematol. 81:12–18. 2006. View Article : Google Scholar : PubMed/NCBI
20	Romero F, Martínez AC, Camonis J and Rebollo A: Aiolos transcription factor controls cell death in T cells by regulating Bcl-2 expression and its cellular localization. EMBO J. 18:3419–3430. 1999. View Article : Google Scholar : PubMed/NCBI
21	Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ: Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol. 139:1281–1292. 1997. View Article : Google Scholar : PubMed/NCBI
22	Nakano K and Vousden KH: PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 7:683–694. 2001. View Article : Google Scholar : PubMed/NCBI
23	Weng C, Li Y, Xu D, Shi Y and Tang H: Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem. 280:10491–10500. 2005. View Article : Google Scholar : PubMed/NCBI
24	Kirito K, Watanabe T, Sawada K, Endo H, Ozawa K and Komatsu N: Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways. J Biol Chem. 277:8329–8337. 2002. View Article : Google Scholar : PubMed/NCBI
25	Minn AJ, Rudin CM, Boise LH and Thompson CB: Expression of bcl-xL can confer a multidrug resistance phenotype. Blood. 86:1903–1910. 1995.PubMed/NCBI
26	Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:479–489. 1997. View Article : Google Scholar : PubMed/NCBI
27	Chen M, Guerrero AD, Huang L, Shabier Z, Pan M, Tan TH and Wang J: Caspase-9-induced mitochondrial disruption through cleavage of anti-apoptotic BCL-2 family members. J Biol Chem. 282:33888–33895. 2007. View Article : Google Scholar : PubMed/NCBI
28	Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, Lee RA, Robbins PD, Fernandes-Alnemri T, Shi Y and Alnemri ES: A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature. 410:112–116. 2001. View Article : Google Scholar : PubMed/NCBI